Search:
hero image

We just investigate the evolutionary origins of the intermolecular DAs in the biosynthesis of Moraceae plant-derived Diels-Alder-type secondary metabolites. The work was recently published on Nature communications.

Biosynthetic enzymes evolutionarily gain novel functions, thereby expanding the structural diversity of natural products to the benefit of host organisms. Diels-Alderases (DAs), functionally unique en…

hero image

We just artificially reconstituted a biosynthetic pathway for the production of baccatin III in tobacco. The work was recently published on Science.

Paclitaxel is a well known anticancer compound. Its biosynthesis involves the formation of a highly functionalized diterpenoid core skeleton (baccatin III) and the subsequent assembly of a phenylisose…

hero image

We just published the first structure of Fhb7 at 2.41 Å and revealed a unique catalytic mechanism of epoxide opening transformation in GST family proteins.

In the era of global climate change, the increasingly severe Fusarium head blight (FHB) and deoxynivalenol (DON) contamination have caused economic losses and brought food and feed safety concerns. Re…

hero image

We just published the first total syntheses of several bis-b-carboline alkaloids, picrasidines G, S, R, and T, and natural product-like derivatives in a divergent manner. The work was recently published on Chemical Science.

Divergent total syntheses of ITHQ-type bis-bcarboline alkaloids by regio-selective formal aza-[4
+ 2] cycloaddition and late-stage C–H
functionalization.

hero image

We just published our remarkable work on identification of the potential antidiabetic target microbial DPP4 by microbial-host-isozyme analyses. The work was recently published on Science.

Microbial-host-isozyme analyses reveal microbial DPP4 as a potential antidiabetic target

hero image

We just published our remarkable biosynthesis work on enzyme-catalyzed intermolecular [4+2] cycloaddition. The work was recently published on Nature Chem.

hero image

We reported Chrysomycin A derivitives, polycarcin V and gilvocarcin V, for the treatment of Tuberculosis. The work was recently published on ACS Central Science.

hero image

We have made big progress in the total synthesis of ent-kaurane diterpenoids

hero image

We reported the first arginine selective crosslinker and published on Nature Communications

hero image

We identified and developed novel selective DYRK 2 inhibitor

Dependence on the 26S proteasome is an Achilles’ heel for triplenegative
breast cancer (TNBC) andmultiplemyeloma (MM). The therapeutic
proteasome inhibitor, bortezomib, successfully targets MM